Articoli - Tumore del seno

Un elenco appositamente selezionato di articoli sottoposti a peer review che trattano i più recenti progressi relativi alla diagnosi e al trattamento delle pazienti affette da carcinoma mammario allo stadio iniziale e carcinoma mammario metastatico.

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

PER SAPERNE DI PIÙ

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

PER SAPERNE DI PIÙ

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

PER SAPERNE DI PIÙ

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

PER SAPERNE DI PIÙ

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial

PER SAPERNE DI PIÙ

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

PER SAPERNE DI PIÙ

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

PER SAPERNE DI PIÙ

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

PER SAPERNE DI PIÙ

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

PER SAPERNE DI PIÙ

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

PER SAPERNE DI PIÙ

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

PER SAPERNE DI PIÙ

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)

PER SAPERNE DI PIÙ

A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer

PER SAPERNE DI PIÙ

Targeting CDK4 and CDK6 in cancer

PER SAPERNE DI PIÙ

Targeting CDK4 and CDK6 in cancer

PER SAPERNE DI PIÙ

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

PER SAPERNE DI PIÙ

Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

PER SAPERNE DI PIÙ

CDK4 and CDK6 kinases: From basic science to cancer therapy

PER SAPERNE DI PIÙ

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

PER SAPERNE DI PIÙ

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

PER SAPERNE DI PIÙ

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

PER SAPERNE DI PIÙ

The role of CDK4/6 inhibitors in early breast cancer

PER SAPERNE DI PIÙ

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

PER SAPERNE DI PIÙ

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

PER SAPERNE DI PIÙ

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

PER SAPERNE DI PIÙ

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

PER SAPERNE DI PIÙ

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

PER SAPERNE DI PIÙ

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

PER SAPERNE DI PIÙ

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

PER SAPERNE DI PIÙ

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

PER SAPERNE DI PIÙ

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis

PER SAPERNE DI PIÙ

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

PER SAPERNE DI PIÙ

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

PER SAPERNE DI PIÙ

Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

PER SAPERNE DI PIÙ

Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

PER SAPERNE DI PIÙ

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

PER SAPERNE DI PIÙ

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

PER SAPERNE DI PIÙ

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

PER SAPERNE DI PIÙ

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

PER SAPERNE DI PIÙ

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

PER SAPERNE DI PIÙ

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

PER SAPERNE DI PIÙ

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

PER SAPERNE DI PIÙ

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

PER SAPERNE DI PIÙ

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PER SAPERNE DI PIÙ

Digita e premi invio per effettuare la ricerca

Questo sito web è destinato esclusivamente all’uso da parte di professionisti del settore sanitario. Continuando a consultare questo sito, confermate di essere operatori sanitari.

 

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Conferma